Piper Sandler lowered the firm’s price target on Cytek Biosciences (CTKB) to $7.50 from $8 keeps an Overweight rating on the shares. The firm cites the company’s quarterly results for the price target change.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTKB:
- Cytek Biosciences Earnings Call: Mixed Sentiment and Growth
- Cytek Biosciences Reports Modest Revenue Growth in Q3 2025
- Cautious Hold on Cytek Biosciences Amid Market Stagnation and Growth Uncertainty
- Cytek Biosciences backs FY25 revenue view $196M-$205M, consensus $195.95M
- Cytek Biosciences reports Q3 EPS (4c), consensus 1c